Evidence map›Paper›PMID 40726983›Full record

ArticleFrontiers in immunology2025

Case Report: The rare pancreatic involvement in Erdheim-Chester disease.

Ji Li, Ming Zhang, Yadan Zou, Jing Zhang, Juanjuan Song, Ting Li, Sheng-Guang Li

Abstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ji LiDepartment of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.
Ming ZhangDepartment of Pathology, Peking University International Hospital, Beijing, China.
Yadan ZouDepartment of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.
Jing ZhangDepartment of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.
Juanjuan SongDepartment of Nuclear Medicine, Peking University International Hospital, Beijing, China.
Ting LiDepartment of Pathology, Peking University International Hospital, Beijing, China.
Sheng-Guang LiDepartment of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Erdheim-Chester disease (ECD) is an exceedingly rare non-Langerhans histiocytosis. While often affecting the skeleton, cardiovascular system, and kidneys, pancreatic involvement remains uncommon and can mimic more prevalent conditions such as autoimmune or chronic pancreatitis. Case Presentation: A 58-year-old female presented with a two-year history of bilateral lower limb edema and a year-long course of recurrent abdominal pain. Imaging suggested necrotizing pancreatitis and retroperitoneal infiltration, yet serum IgG4 levels were normal. A CT-guided biopsy of the pancreas and retroperitoneum revealed diffuse proliferation of foamy histiocytes (CD68 Discussion: ECD can present with non-specific clinical features, leading to frequent misdiagnoses. Involvement of the pancreas, as demonstrated here, is particularly rare. The discovery of the BRAF V600E mutation underscores the importance of molecular testing for both diagnostic confirmation and therapeutic stratification. The immunopathogenesis of ECD involves activated macrophages and aberrant MAPK signaling, which drive chronic inflammation and tissue fibrosis. Conclusion: This case highlights the diagnostic challenges of pancreatic ECD and underscores the critical value of an integrated approach-including imaging, immunohistochemistry, and molecular analysis-in achieving timely diagnosis. Early recognition and targeted therapy may significantly improve outcomes for patients with BRAF-mutant ECD.

Indexed as

Erdheim-Chester DiseasePancreasCOVID-19FemaleHumansMiddle AgedMutationProto-Oncogene Proteins B-rafSARS-CoV-2BRAF protein, humanProto-Oncogene Proteins B-rafBRAF V600EErdheim-Chester diseasefoamy histiocytesMAPK pathwaynon-Langerhans histiocytosispancreatic involvement

Identifiers

PMID40726983
PMCPMC12301201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.